RVT-3101 for the Treatment of Moderate to Severe Active Crohn's Disease
Status:
Not yet recruiting
Trial end date:
2025-11-01
Target enrollment:
Participant gender:
Summary
This Phase 2, randomized, double-blind, multicenter, induction and maintenance study is
designed to evaluate the safety and efficacy of RVT-3101 in adult participants with moderate
to severe active Crohn's disease.